(Reuters) - Europe's medicines regulator said on Friday Eli Lilly and Co's antibody drug combination can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness.
The recommendation can now be used as guidance in individual European nations on the possible use of the combination of bamlanivimab and etesevimab, before a broader approval is given, the European Medicines Agency (EMA) said. (https://bit.ly/3kMpkZr)
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!